Advanced and metastatic soft tissue sarcoma, a review of aajcc 8th edition staging and the use of olaratumab.


Journal of Cancer Immunology and Therapy is an academic journal and aims to publish most complete and reliable source of information on the discoveries and current developments in the mode of original articles, review articles, case reports, short communications, etc. in all areas of the field and making them freely available through online without any restrictions or any other subscriptions to researchers worldwide. The journal selects the articles to be published with a single bind, peer review system, following the practices of good scholarly journals. It supports the open access policy of making scientific research accessible to one and all. 

We are sharing one of the most cited article from our journal. Article entitled “Advanced and metastatic soft tissue sarcoma, a review of aajcc 8th edition staging and the use of olaratumab.” was well written by Dr. Hari A Deshpande.


Soft tissue sarcomas represent a rare but histologically variable type of solid malignancy. Doxorubicin based regimens either alone or in combination with other agents had remained unchanged for decades as the standard first line treatment for metastatic disease. The definition of metastatic disease has been changed with the introduction of the American Joint Commission on Cancer (AJCC) 8th edition guidelines. The overall survival for patients with metastatic disease, despite the approval of 2 new agents, had been in the region of 12-19 months. Olaratumab is a monoclonal antibody directed against PDGFR alpha. The results of a randomized phase 2 study comparing olaratumab plus doxorubicin with doxorubicin alone, showed a statistically significant improvement in progression free survival (PFS) up to 6 months, and a more dramatic improvement in overall survival (OS) to 26.9 months. This was the first randomized trial to show a significant improvement in overall survival compared to doxorubicin alone. Olaratumab has been granted accelerated approval by the Food and Drug Administration of the United States of America. Ongoing trials are underway to further demonstrate the mechanism of action and also to confirm the benefit in a Phase III study.

Click the link to view full article:

Manuscripts related to the above relevant topics can be submitted to the Journal through online or as an attachment to the E-mail: High quality submissions are expected to maintain the standard of the journal

Media Contact,

Shelley Brown
Editorial Team
Journal of Cancer Immunology and Therapy
WhatsApp: +1-97-333-4405